<< Back To Search

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT04484623
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
This study will test if a new drug called belantamab mafodotin is safe and helpful when it is used with two other drugs, pomalidomide and dexamethasone. They will compare how well this combination works compared to a combination of two other drugs, pomalidomide and bortezomib, with dexamethasone. The study is for people with a type of cancer called multiple myeloma that has come back after treatment or did not get better with treatment.
Third Opinion AI Generated Synopsis

Trial Summary
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: